WEBSITE BSE:543264 NSE: NURECA Inc. Year: 2016 Industry: Medical Equipment/Supplies/Accessories
Last updated: 15:50
Nureca Limited, a B2C agency, engages in the domestic healthcare and well-being products commercial enterprise in India. It gives chronic disease merchandise, inclusive of nebulizers, blood pressure video display units, finger pulse oximeter, glucose meter, and thermometer; orthopaedic products, which includes massagers, ache monitors, posture correctors, and rehabilitation products; and humidifiers and steamers, non-public scales, yoga and exercising, health monitoring, and dental and personal care products. The organisation also provides moth...Read More
Nureca Limited, a B2C agency, engages in the domestic healthcare and well-being products commercial enterprise in India. It gives chronic disease merchandise, inclusive of nebulizers, blood pressure video display units, finger pulse oximeter, glucose meter, and thermometer; orthopaedic products, which includes massagers, ache monitors, posture correctors, and rehabilitation products; and humidifiers and steamers, non-public scales, yoga and exercising, health monitoring, and dental and personal care products. The organisation also provides mother and toddler care products comprising baby feeding, carry cots, infant skincare, and bottle heaters and steamers; nutritional supplements and weight control merchandise; and ECG, health tracker, and smart weighing scale merchandise. Nureca Ltd offers its merchandise underneath Dr Trust, Dr Physio, and Trumom brands. The enterprise sells its products via third party e-trade players, vendors, and retailers; and through its website, drtrust.In. Nureca Ltd was founded in 2016 and is primarily based in Chandigarh, India. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹269 Cr.
Stock P/E 317.9
P/B 1.4
Current Price ₹281.9
Book Value ₹ 196.3
Face Value 10
52W High ₹354
Dividend Yield 0%
52W Low ₹ 198
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 31 | 22 | 17 | 20 | 31 | 26 | 32 | 34 | 38 | 40 |
| Other Income | 3 | 6 | -1 | 6 | 3 | 1 | 2 | 3 | 2 | 2 |
| Total Income | 35 | 28 | 16 | 26 | 34 | 28 | 34 | 37 | 40 | 42 |
| Total Expenditure | 30 | 27 | 21 | 23 | 34 | 30 | 31 | 35 | 34 | 36 |
| Operating Profit | 5 | 2 | -6 | 3 | 1 | -3 | 3 | 2 | 6 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 4 | 1 | -6 | 3 | -0 | -3 | 2 | 1 | 5 | 5 |
| Provision for Tax | 1 | 1 | -2 | 1 | 0 | -0 | -0 | 0 | 1 | 1 |
| Profit After Tax | 3 | 0 | -4 | 2 | -0 | -3 | 2 | 1 | 4 | 4 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 3 | 0 | -4 | 2 | -0 | -3 | 2 | 1 | 4 | 4 |
| Adjusted Earnings Per Share | 2.9 | 0.2 | -4.1 | 1.7 | -0.5 | -2.8 | 2.5 | 0.8 | 3.6 | 3.7 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 20 | 62 | 99 | 213 | 256 | 111 | 92 | 110 | 144 |
| Other Income | 0 | 0 | 0 | 3 | 8 | 7 | 11 | 13 | 9 |
| Total Income | 20 | 62 | 99 | 216 | 263 | 118 | 102 | 122 | 153 |
| Total Expenditure | 16 | 53 | 90 | 152 | 200 | 126 | 102 | 117 | 136 |
| Operating Profit | 4 | 9 | 10 | 64 | 63 | -8 | 0 | 5 | 16 |
| Interest | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 4 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 4 | 9 | 9 | 62 | 61 | -11 | -3 | 1 | 13 |
| Provision for Tax | 1 | 3 | 2 | 16 | 16 | -2 | -1 | 0 | 2 |
| Profit After Tax | 3 | 6 | 6 | 46 | 45 | -8 | -2 | 1 | 11 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 3 | 6 | 6 | 46 | 45 | -8 | -2 | 1 | 11 |
| Adjusted Earnings Per Share | 444.6 | 889.4 | 913.6 | 46.4 | 45 | -8.3 | -1.8 | 0.8 | 10.6 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 20% | -25% | 2% | 0% |
| Operating Profit CAGR | 0% | -57% | -13% | 0% |
| PAT CAGR | 0% | -72% | -30% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -22% | -15% | NA% | NA% |
| ROE Average | 0% | -2% | 14% | 90% |
| ROCE Average | 1% | -2% | 19% | 74% |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 2 | 8 | 15 | 163 | 203 | 195 | 193 | 194 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 9 | 1 | 0 | 0 | 0 | 1 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 2 | 4 | 0 | -2 | -1 |
| Total Current Liabilities | 5 | 15 | 10 | 24 | 45 | 9 | 9 | 12 |
| Total Liabilities | 7 | 24 | 34 | 190 | 252 | 204 | 200 | 207 |
| Fixed Assets | 0 | 1 | 1 | 4 | 10 | 9 | 7 | 9 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 3 | 9 | 1 | 8 |
| Total Current Assets | 7 | 23 | 33 | 186 | 239 | 187 | 193 | 190 |
| Total Assets | 7 | 24 | 34 | 190 | 252 | 204 | 200 | 207 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 17 | 8 | 1 | 14 |
| Cash Flow from Operating Activities | 0 | 0 | -8 | 35 | 1 | 10 | -3 | -19 |
| Cash Flow from Investing Activities | -0 | -0 | -0 | -110 | -3 | -16 | 18 | 8 |
| Cash Flow from Financing Activities | -0 | -0 | 8 | 92 | -7 | -2 | -1 | -0 |
| Net Cash Inflow / Outflow | 0 | 0 | -0 | 17 | -9 | -8 | 14 | -11 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 17 | 8 | 1 | 14 | 3 |
| # | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 444.57 | 889.43 | 913.57 | 46.37 | 44.96 | -8.25 | -1.79 | 0.85 |
| CEPS(Rs) | 445.43 | 897.57 | 967 | 46.8 | 46.44 | -5.86 | 0.57 | 3.18 |
| DPS(Rs) | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 104.29 | 993.57 | 1990.71 | 163.1 | 203.2 | 194.88 | 193.11 | 194.29 |
| Core EBITDA Margin(%) | 21.82 | 14.2 | 9.37 | 27.36 | 20.55 | -12.87 | -10.23 | -6.4 |
| EBIT Margin(%) | 21.88 | 14.25 | 9.07 | 28.42 | 22.85 | -8.83 | -2.06 | 2.1 |
| Pre Tax Margin(%) | 21.56 | 13.87 | 8.32 | 27.71 | 22.57 | -9.21 | -2.54 | 1.1 |
| PAT Margin (%) | 15.52 | 9.77 | 6.18 | 20.62 | 16.64 | -7.08 | -1.79 | 0.69 |
| Cash Profit Margin (%) | 15.55 | 9.86 | 6.55 | 20.8 | 17.19 | -5.03 | 0.57 | 2.61 |
| ROA(%) | 44.35 | 40.78 | 22.3 | 41.38 | 20.33 | -3.62 | -0.89 | 0.42 |
| ROE(%) | 426.3 | 162.03 | 61.23 | 52.39 | 24.55 | -4.14 | -0.92 | 0.44 |
| ROCE(%) | 255.06 | 179.97 | 56.7 | 67.61 | 33.57 | -5.17 | -1.06 | 1.31 |
| Receivable days | 30.69 | 30.18 | 38.39 | 10.65 | 2.11 | 11.25 | 10.79 | 7.39 |
| Inventory Days | 64.42 | 48.92 | 52.9 | 43.16 | 67.53 | 152.88 | 119.26 | 105.87 |
| Payable days | 172.97 | 68.29 | 44.04 | 26.74 | 18.53 | 23.46 | 30.6 | 31.48 |
| PER(x) | 0 | 0 | 0 | 12.98 | 30.3 | 0 | 0 | 248.64 |
| Price/Book(x) | 0 | 0 | 0 | 3.69 | 6.7 | 1.54 | 1.32 | 1.08 |
| Dividend Yield(%) | 0 | 0 | 0 | 0.33 | 0.22 | 0 | 0 | 0 |
| EV/Net Sales(x) | -0 | 0.01 | 0.1 | 2.23 | 5 | 2.06 | 2.29 | 1.52 |
| EV/Core EBITDA(x) | -0.01 | 0.04 | 1 | 7.41 | 20.22 | -29.03 | 685.11 | 34.01 |
| Net Sales Growth(%) | 0 | 208.7 | 60.63 | 114.69 | 19.72 | -56.44 | -17.42 | 19.29 |
| EBIT Growth(%) | 0 | 107.07 | 3.27 | 581.55 | -3.46 | -116.67 | 80.03 | 224.43 |
| PAT Growth(%) | 0 | 100.06 | 2.71 | 625.16 | -3.05 | -118.35 | 78.25 | 147.16 |
| EPS Growth(%) | 0 | 100.06 | 2.71 | -94.92 | -3.05 | -118.35 | 78.25 | 147.16 |
| Debt/Equity(x) | 0 | 0.06 | 0.7 | 0.01 | 0 | 0 | 0 | 0.01 |
| Current Ratio(x) | 1.32 | 1.5 | 3.45 | 7.78 | 5.28 | 21 | 20.77 | 15.32 |
| Quick Ratio(x) | 0.65 | 0.62 | 1.72 | 6.24 | 3.89 | 17.12 | 17.44 | 12.1 |
| Interest Cover(x) | 68.55 | 37.38 | 12.14 | 39.89 | 83.3 | -22.87 | -4.2 | 2.11 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 63.24 | 63.24 | 63.24 | 63.24 | 63.77 | 64.06 | 64.3 | 64.33 | 64.97 | 68.09 |
| FII | 0.1 | 0.07 | 0.07 | 0.07 | 0.69 | 0.36 | 1.07 | 0.07 | 0.07 | 0.08 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 36.66 | 36.69 | 36.69 | 36.69 | 35.53 | 35.58 | 34.62 | 35.6 | 34.95 | 31.82 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.63 | 0.63 | 0.63 | 0.63 | 0.64 | 0.64 | 0.64 | 0.64 | 0.65 | 0.65 |
| FII | 0 | 0 | 0 | 0 | 0.01 | 0 | 0.01 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.37 | 0.37 | 0.37 | 0.37 | 0.36 | 0.36 | 0.35 | 0.36 | 0.35 | 0.3 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.95 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
